Evidence map›Paper›PMID 38528630›Full record

ArticleEuropean journal of medical research2024

Integrative analysis revealed a correlation of PIAS family genes expression with prognosis, immunomodulation and chemotherapy.

Qiqi Zhang, Junkui Zhang, Tianyi Lan, Jiayue He, Bin Lei, Hongnan Wang, Zhiqiang Mei, Chaoxiang Lv

Open access · goldAbstract read
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Pan-cancer characterization ofTranslational cancer research · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Crosstalk ofOncoTargets and therapy · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qiqi Zhang *The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Junkui Zhang *Pharmaceutical Institute, Henan University, Kaifeng, 475004, China.
Tianyi LanThe Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Jiayue HeThe Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Bin LeiThe Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Hongnan WangCollege of Integrative Chinese and Western Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Zhiqiang MeiThe Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China. xuguangyin1@163.com.
Chaoxiang LvThe Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China. lvchaoxiang@126.com.
Southwest Medical University · CNHenan University · CN

Funding

Doctoral research start-up Fund 00170049/41
6 · The paper itself

Abstract

backgroundProtein inhibitor of activated STATs (PIAS) has pleiotropic biological effects, such as protein post-translational modification, transcriptional coregulation and gene editing. It is reported that PIAS family genes are also correlated with immune cells infiltration in cancers that highlights their unnoticed biological role in tumor progression. However, the relationship of their expression with prognosis, immune cell infiltration, tumor microenvironment, and immunotherapy in pan-cancer has been rarely reported.

methodsThe multi-omics data were used to investigate the expression level of PIAS family members in pan-cancer, and the prognostic value of their expression in different tumors was analyzed by univariate Cox regression and Kaplan-Meier. Correlation analysis was used to investigate the relationship of PIAS gene expression with tumor microenvironment, immune infiltrating subtypes, stemness score and drug sensitivity. In addition, we also used wound healing and transwell assays to verify the biological effects of PIAS family gene expression on invasion and metastasis of HCC cells.

resultsWe found that PIAS family genes expression is significantly heterogeneous in tumors by multi-genomic analysis, and associated with poor prognosis in patients with multiple types of cancer. Furthermore, we also found that genetic alterations of PIAS family genes were not only common in different types of human tumors, but were also significantly associated with disease-free survival (DFS) across pan-cancer. Single-cell analysis revealed that PIAS family genes were mainly distributed in monocytes/macrophages. Additionally, we also found that their expression was associated with tumor microenvironment (including stromal cells and immune cells) and stemness score (DNAss and RNAss). Drug sensitivity analysis showed that PIAS family genes were able to predict the response to chemotherapy and immunotherapy. PIAS family genes expression is closely related to tumor metastasis, especially PIAS3. High PIAS3 expression significantly promotes the migration and invasion of liver cancer cell lines (HCC-LM3 and MHCC97-H).

conclusionsTaking together, these findings contribute to determine whether the PIAS family genes are a potential oncogenic target gene, which have important contribution for the development of cancer immunotherapy.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansImmunomodulationImmunotherapyMolecular ChaperonesPrognosisProtein Inhibitors of Activated STATTumor MicroenvironmentMolecular ChaperonesPIAS3 protein, humanProtein Inhibitors of Activated STATImmune cell infiltrationImmunotherapyPIASSingle-cell RNA-SeqTumor microenvironment

Identifiers

PMID38528630
PMCPMC10962104
OpenAlexW4393157441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.